3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
5
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Disease Progression
2
Triple Negative Breast Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Interventions
Leucovorin
22
Fluorouracil
22
Gemcitabine
21
Capecitabine
21
Paclitaxel
20
Docetaxel
20
Irinotecan
15
Carboplatin
15
Radiosurgery
14
Oxaliplatin
13
Cisplatin
13
Bevacizumab
13
Zoledronic Acid
12
pembrolizumab
11
Radiotherapy
11
Fulvestrant
11
palbociclib
9
Pemetrexed
9
Drug Therapy
9
130-nm albumin-bound paclitaxel
9
Surgical Procedures, Operative
7
Letrozole
7
Ibandronic Acid
7
abemaciclib
6
Trastuzumab
6
Prednisone
6
Vinorelbine
5
Folfox protocol
5
Floxuridine
5
Doxorubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasm Metastasis
×
capivasertib
×
Clear all
NCT07281833
2026-02-27
CAPIcorn
West German Study Group
Phase 3
Recruiting
250 enrolled
NCT05348577
2025-01-27
CAPItello280
AstraZeneca
Phase 3
Active not recruiting
1,035 enrolled